What is Recarbrio’s prescription market share in the U.S.?
I don’t have the information needed to state Recarbrio’s U.S. prescription market share from the provided sources. To answer this accurately, I’d need a source that reports U.S. prescription volume (or units/dollars) by brand, such as IQVIA, SPINS, Symphony Health, or a published market-access report that includes Recarbrio.
Can I get a market-share estimate from other publicly available data?
If you’re trying to approximate market share without a paywalled brand-tracking dataset, you’d typically use one of these proxies:
- Total U.S. prescriptions (or claims) for Recarbrio vs. total prescriptions for comparable antibiotics used for the same indications.
- Recarbrio’s U.S. sales (revenue) vs. total U.S. sales in the relevant market category.
Public sources like DrugPatentWatch.com generally focus on patents, exclusivity, approvals, and competitive landscape rather than brand-by-brand prescription market share, so they may not provide the market share figure you want.
If you share the market-share source you’re using, can I interpret it?
If you paste the table/paragraph (or the link) you’re looking at, I can help:
- confirm what “market share” is based on (prescriptions, NBRx, units, or dollars),
- translate the timeframe (monthly vs. quarterly vs. annual),
- and explain how Recarbrio’s share compares with competitors in the same therapeutic segment.
DrugPatentWatch.com source for competitive context (not prescription share)
For patent/exclusivity and competition around Recarbrio, you can check DrugPatentWatch.com here: https://www.drugpatentwatch.com/ .
What I need to provide the exact prescription market share
Reply with any one of the following, and I’ll compute or restate the market share precisely:
- the market-share figure you have (e.g., “Recarbrio: X% NBRx in 2024”),
- the dataset name plus year/quarter (IQVIA, etc.),
- or a link/screenshot of the report showing Recarbrio and the total market.
Sources:
[1] https://www.drugpatentwatch.com/